VistaGen Therapeutics Financials

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

VistaGen Therapeutics Stock Summary

VistaGen Therapeutics competes with Synlogic, AC Immune, Entera Bio, Tempest Therapeutics, and Quoin Pharmaceuticals. VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system . VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California. Vistagen Therap operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 38 people.

VistaGen Therapeutics Key Financial Ratios

VistaGen Therapeutics Key Balance Sheet Accounts

VistaGen Therapeutics Key Income Statement Accounts

VistaGen Therapeutics Key Cash Accounts

VistaGen Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining VistaGen Therapeutics's current stock value. Our valuation model uses many indicators to compare VistaGen Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across VistaGen Therapeutics competition to find correlations between indicators driving VistaGen Therapeutics's intrinsic value. More Info.VistaGen Therapeutics is rated fourth in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, VistaGen Therapeutics' Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the VistaGen Therapeutics' earnings, one of the primary drivers of an investment's value.

VistaGen Therapeutics Systematic Risk

Today, most investors in VistaGen Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various VistaGen Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of VistaGen Therapeutics growth as a starting point in their analysis.

Along with financial statement analysis, the daily predictive indicators of VistaGen Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of VistaGen Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of VistaGen Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing VistaGen Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build VistaGen Therapeutics's daily price indicators and compare them against related drivers.

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in VistaGen Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in VistaGen Stock, please use our How to Invest in VistaGen Therapeutics guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of VistaGen Therapeutics. If investors know VistaGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about VistaGen Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of VistaGen Therapeutics is measured differently than its book value, which is the value of VistaGen that is recorded on the company's balance sheet. Investors also form their own opinion of VistaGen Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is VistaGen Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because VistaGen Therapeutics' market value can be influenced by many factors that don't directly affect VistaGen Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between VistaGen Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if VistaGen Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, VistaGen Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.